US OptionsDetailed Quotes
SUPN241220C22000
- 0.00
- 0.000.00%
15min DelayClose Nov 22 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest22.00Strike Price0.00Turnover165.90%IV-39.26%PremiumDec 20, 2024Expiry Date14.22Intrinsic Value100Multiplier27DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9084Delta0.0100Gamma2.39Leverage Ratio-0.0515Theta0.0133Rho2.17Eff Leverage0.0163Vega
Supernus Pharmaceuticals Stock Discussion
Supernus Pharmaceuticals 3Q Rev $175.7M
Supernus Resubmits New Drug Application for Parkinson's Treatment Device
Supernus Pharmaceuticals resubmitted its new-drug application for a device to treat patients with Parkinson's disease to the Food and Drug Administration.
The Rockville, Md. biopharmaceutical company said on Thursday it believes it has addressed the questions in an April letter from the FDA about the review of its SPN-830 apomorphine-infusion device to treat "off" episodes in Parkinso...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$Supernus Pharmaceuticals (SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech (LEGN.US)$ & $Johnson & Johnson (JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca (AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio (TSVT.US)$ & $Bristol-Myers Squibb (BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals (VNDA.US)$...
waiting patiently for fda 😌🙏
$Akebia Therapeutics (AKBA.US)$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$Merck & Co (MRK.US)$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$AstraZeneca (AZN.US)$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$Regeneron Pharmaceuticals (REGN.US)$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$AstraZeneca (AZN.US)$ : 🤔
⇒...
$Vanda Pharmaceuticals (VNDA.US)$ $Legend Biotech (LEGN.US)$ $Supernus Pharmaceuticals (SUPN.US)$ $ImmunityBio (IBRX.US)$ $Aquestive Therapeutics (AQST.US)$ $X4 Pharmaceuticals (XFOR.US)$ $Liquidia (LQDA.US)$ $Neurocrine Biosciences (NBIX.US)$ $Moderna (MRNA.US)$ $Day One Biopharmaceuticals (DAWN.US)$
...
No comment yet